Is Pfizer Stock Truly Undervalued? By: The Financial Jester June 28, 2022 Ahead of next Tuesday’s earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis suggests stock ought to be valued ~$50, but this depends…

Funny Interview with Bank of America Managing Director on GM Earnings Report The Numbers Game General Motors (GM) reported fiscal fourth quarter earnings that exceeded analyst expectations on both revenue and profit fronts; despite this news, GM shares are down by over 10% at the time of this interview’s posting. Bank of America managing director…

The Exciting Future of EFX in Treating Cirrhosis Exciting news has recently emerged in the pharmaceutical world, as a company’s stock surged over 100% following positive results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis in patients with MASH. The study showed a significant reversal of cirrhosis, with 39% of…

Expanding the Use of Ozempic: A Win for Patients Breaking News from the FDA Exciting news has just been announced in the world of diabetes treatment. The Food and Drug Administration has officially approved the use of Novo Nordisk’s Ozempic for patients with chronic kidney disease and diabetes. This approval marks a significant step forward…

Recovery Options for MGP Ingredients, Inc. Investors New York City, NY / Accesswire / January 28, 2025 If you have suffered a financial loss due to your investment in MGP Ingredients, Inc. (NASDAQ:MGPI), you may have options for potential recovery under the federal securities laws. Joseph E. Levi, Esq., is available to provide more information…